EUVIMEDEUVIMED entdecken
Crossref

KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia

Yibo Wu, Xiaolin Yuan, Xiaoyu Lai, Lizhen Liu, Yue Liang, Luxin Yang, Panpan Zhu, Jimin Shi, Jian Yu, Yanmin Zhao, Weiyan Zheng, Jie Sun und 6 weitere

Cancer · 2025-07 · 131 (13)

DOI: 10.1002/cncr.35941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 18.06.2025. Verfasst von Yibo Wu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloid-Lymphoid Leukemia Protein, Mutation, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

KMT2A (11q23)‐rearranged acute myeloid leukemia ( KMT2A ‐r AML) represents a clinically aggressive subtype with heterogeneous outcomes. Current evidence remains inconclusive regarding the prognostic relevance of fusion partners in 11q23/ KMT2A ‐rearranged AML. The comprehensive mutational landscape and prognostic implications of co‐occurring driver mutations remain poorly characterized.

Methods

A comprehensive clinicogenomic analysis of 159 de novo KMT2A ‐r AML patients was conducted to assess the correlation between molecular profiles and clinical outcomes.

Results

Notably, the KMT2A::MLLT4 subgroup exhibited significantly higher KRAS mutation frequencies compared to other rearrangement groups ( p < .05). Survival analysis revealed that the KMT2A::MLLT4 cohort demonstrated trends toward inferior overall survival (OS) and increased cumulative incidence of relapse (CIR) relative to other rearrangement subgroups. Stratified by mutational status, patients with KRAS mutations exhibited significantly inferior 2‐year OS rates (24.6% vs. 50.5%; p = .001) and higher 2‐year CIR (56.3% vs. 34.6%; p = .018) compared to KRAS wild‐type counterparts. This adverse prognostic association remained in the transplanted cohort (OS: 32.3% vs. 73.5%; p < .001; CIR: 73.6% vs. 23.0%; p < .001). In contrast, mutations in NRAS , FLT3 did not demonstrate statistically significant associations with OS or CIR in either the overall cohort or transplant subgroup. Multivariable Cox regression confirmed KRAS mutation as an independent adverse prognostic factor for both 2‐year OS (hazard ratio [HR], 0.51; 95% CI, 0.31–0.84; p = .008) and CIR (HR, 1.80; 95% CI, 1.04–3.12; p = .037) in the overall cohort. This association persisted in the transplanted patients subgroup (OS: HR, 0.18; 95% CI, 0.06–0.52; p = .001; CIR: HR, 3.89; 95% CI, 1.05–14.37; p = .042).

Conclusions

These results demonstrate the independent prognostic value of KRAS mutations across treatment modalities, including both conventional chemotherapy and hematopoietic stem cell transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinMutationProto-Oncogene Proteins p21(ras)Histone-Lysine N-MethyltransferaseHumansMaleFemaleMiddle AgedPrognosisAgedAdultGene RearrangementYoung AdultAdolescentAged, 80 and over

Stichwörter der Autor:innen

11q23/KMT2AKRAS mutationsacute myeloid leukemiaprognosisrelapse

Substanzen

Myeloid-Lymphoid Leukemia ProteinKMT2A protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Histone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.
  • Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China.
  • Department of Hematology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.

ORCID-Profile: Zhen Cai, He Huang, Yi Luo

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, Y., Yuan, X., Lai, X., Liu, L., Liang, Y., Yang, L., Zhu, P., Shi, J., Yu, J., Zhao, Y., Zheng, W., Sun, J., Zhu, Y., Wu, W., Cai, Z., Huang, H., Pei, S., & Luo, Y. (2025). KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia. Cancer, 131(13). https://doi.org/10.1002/cncr.35941

Vancouver

Wu Y, Yuan X, Lai X, Liu L, Liang Y, Yang L, et al. KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia. Cancer. 2025;131(13). doi:10.1002/cncr.35941

BibTeX
@article{Wu2025,
  author = {Wu, Yibo and Yuan, Xiaolin and Lai, Xiaoyu and Liu, Lizhen and Liang, Yue and Yang, Luxin and Zhu, Panpan and Shi, Jimin and Yu, Jian and Zhao, Yanmin and Zheng, Weiyan and Sun, Jie and Zhu, Yuanyuan and Wu, Wenjun and Cai, Zhen and Huang, He and Pei, Shanshan and Luo, Yi},
  title = {KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {13},
  doi = {10.1002/cncr.35941}
}
Kostenlos starten →